{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:17:38Z","timestamp":1791299858883,"version":"4.1.0"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The incidence and mortality rates of liver cancer in China remain elevated. Although early-stage liver cancer is amenable to surgical resection, a significant proportion of patients are diagnosed at advanced stages. Currently, in addition to surgical resection for hepatocellular carcinoma, the primary treatment modalities predominantly include chemotherapy. The widespread use of chemotherapy, which non-selectively targets both malignant and healthy cells, often results in substantial immunosuppression. Simultaneously, the accumulation of chemotherapeutic agents can readily induce drug resistance upon reaching the physiological threshold, thereby diminishing the efficacy of these treatments. Besides chemotherapy, there exist targeted therapy, immunotherapy and other therapeutic approaches. Nevertheless, the development of drug resistance remains an inevitable challenge. To address these challenges, we turn to nanomedicine, an emerging and widely utilized discipline that significantly influences medical imaging, antimicrobial strategies, drug delivery systems, and other related areas. Stable and safe nanomaterials serve as effective carriers for delivering anticancer drugs. They enhance the precision of drug targeting, improve bioavailability, and minimize damage to healthy cells. This review focuses on common nanomaterial carriers used in hepatocellular carcinoma (HCC) treatment over the past five years. The following is a summary of the three drugs: Sorafenib, Gefitinib, and lenvatinib. Each drug employs distinct nanomaterial delivery systems, which result in varying levels of bioavailability, drug release rates, and therapeutic efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1496498","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:13:59Z","timestamp":1740726839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Nanomaterials for liver cancer targeting: research progress and future prospects"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiahong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yefu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12951-022-01615-2","article-title":"Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma","volume":"20","author":"Xu","year":"2022","journal-title":"J Nanobiotechnology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.018","article-title":"Heterogeneity of liver cancer and personalized therapy","volume":"379","author":"Li","year":"2016","journal-title":"Cancer Lett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver cancer: connections with obesity, fatty liver, and cirrhosis","volume":"67","author":"Marengo","year":"2016","journal-title":"Annu Rev Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer","volume":"70","author":"Greten","year":"2019","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.005","article-title":"Liver transplantation 2023: status report, current and future challenges","volume":"21","author":"Terrault","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2021.05.031","article-title":"Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer","volume":"130","author":"Liu","year":"2021","journal-title":"Acta Biomater"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300878","article-title":"Nano ultrasound contrast agent for synergistic chemo-photothermal therapy and enhanced immunotherapy against liver cancer and metastasis","volume":"10","author":"Qiu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12951-023-01804-7","article-title":"Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art","volume":"21","author":"Wu","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0123-5","article-title":"Metabolic regulation of cell growth and proliferation","volume":"20","author":"Zhu","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0125-9","article-title":"Host tissue determinants of tumour immunity","volume":"19","author":"Salmon","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2018.07.003","article-title":"Extracellular vesicles and anti-cancer drug resistance","volume":"1870","author":"Namee","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"ODonnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu Rev Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12943-022-01680-z","article-title":"Biological and pharmacological roles of m(6)A modifications in cancer drug resistance","volume":"21","author":"Liu","year":"2022","journal-title":"Mol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127201","article-title":"Adipocyte and lipid metabolism in cancer drug resistance","volume":"129","author":"Cao","year":"2019","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00078-0","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"25","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0630","article-title":"Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials","volume":"28","author":"Yukami","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.051","article-title":"Targeted and immune-based therapies for hepatocellular carcinoma","volume":"156","author":"Greten","year":"2019","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: An EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic therapy and sequencing options in advanced hepatocellular carcinoma: A systematic review and network meta-analysis","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071715","article-title":"Hypoxia, metabolic reprogramming, and drug resistance in liver cancer","volume":"10","author":"Bao","year":"2021","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1039\/C9NR04902A","article-title":"Recent advances in multiphoton microscopy combined with nanomaterials in the field of disease evolution and clinical applications to liver cancer","volume":"11","author":"Lin","year":"2019","journal-title":"Nanoscale"},{"key":"B45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","article-title":"De novo lipogenesis in health and disease","volume":"63","author":"Ameer","year":"2014","journal-title":"Metabolism"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141223801","article-title":"Establishment of metabolism and transport pathways in the rodent and human fetal liver","volume":"14","author":"Moscovitz","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/BF01797915","article-title":"Detoxification pathways in the liver","volume":"14","author":"Grant","year":"1991","journal-title":"J Inherit Metab Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-022-00698-3","article-title":"Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy","volume":"17","author":"Guo","year":"2022","journal-title":"Nat Protoc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42008","article-title":"Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s11658-022-00394-w","article-title":"Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via eChinacoside nanodelivery","volume":"27","author":"Wang","year":"2022","journal-title":"Cell Mol Biol Lett"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.3390\/ijms20122918","article-title":"Curcumin-loaded mesoporous silica nanoparticles markedly enhanced cytotoxicity in hepatocellular carcinoma cells","volume":"20","author":"Kong","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.9b05531","article-title":"Dual-aptamer modified graphene field-effect transistor nanosensor for label-free and specific detection of hepatocellular carcinoma-derived microvesicles","volume":"92","author":"Wu","year":"2020","journal-title":"Anal Chem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.3390\/ijms22115786","article-title":"Graphene oxide loaded with protocatechuic acid and chlorogenic acid dual drug nanodelivery system for human hepatocellular carcinoma therapeutic application","volume":"22","author":"Buskaran","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54822","article-title":"Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma","volume":"11","author":"Kong","year":"2021","journal-title":"Theranostics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c04835","article-title":"Surface topography of polyethylene glycol shell nanoparticles formed from bottlebrush block copolymers controls interactions with proteins and cells","volume":"15","author":"Grundler","year":"2021","journal-title":"ACS Nano"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2019.1669558","article-title":"Lipid-based nanoparticle formulations for small molecules and RNA drugs","volume":"16","author":"Ickenstein","year":"2019","journal-title":"Expert Opin Drug Delivery"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S132434","article-title":"Liposomal curcumin and its application in cancer","volume":"12","author":"Feng","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e2001451","DOI":"10.1002\/adhm.202001451","article-title":"Advances in magnetic nanoparticle-mediated cancer immune-theranostics","volume":"10","author":"Cheng","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.09.025","article-title":"Magnetic nanoparticles as versatile carriers for enzymes immobilization: A review","volume":"120","author":"Bilal","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"110724","DOI":"10.1016\/j.colsurfb.2019.110724","article-title":"Intracellular pH-propelled assembly of smart carbon nanodots and selective photothermal therapy for cancer cells","volume":"188","author":"Zhang","year":"2020","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.actbio.2021.04.054","article-title":"Mitochondria-targeted graphene for advanced cancer therapeutics","volume":"129","author":"Tabish","year":"2021","journal-title":"Acta Biomater"},{"key":"B63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/bios12050269","article-title":"Properties and applications of graphene and its derivatives in biosensors for cancer detection: A comprehensive review","volume":"12","author":"Pourmadadi","year":"2022","journal-title":"Biosensors (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"122026","DOI":"10.1016\/j.jhazmat.2020.122026","article-title":"Preparation, environmental application and prospect of biochar-supported metal nanoparticles: A review","volume":"388","author":"Liu","year":"2020","journal-title":"J Hazard Mater"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42471","article-title":"Ultrasmall gold nanoparticles in cancer diagnosis and therapy","volume":"10","author":"Fan","year":"2020","journal-title":"Theranostics"},{"key":"B66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1517\/17425240802622096","article-title":"Nanoparticles for human liver-specific drug and gene delivery systems: in vitro and in vivo advances","volume":"6","author":"Kasuya","year":"2009","journal-title":"Expert Opin Drug Delivery"},{"key":"B67","doi-asserted-by":"publisher","first-page":"113642","DOI":"10.1016\/j.jpba.2020.113642","article-title":"Analytical characterization of liposomes and other lipid nanoparticles for drug delivery","volume":"192","author":"Fan","year":"2021","journal-title":"J Pharm BioMed Anal"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202308780","article-title":"NIR-II photoacoustic imaging-guided oxygen delivery and controlled release improves photodynamic therapy for hepatocellular carcinoma","volume":"36","author":"Zeng","year":"2024","journal-title":"Adv Mater"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202663","article-title":"Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma","volume":"12","author":"Su","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"B71","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/IJN.S37859","article-title":"Molecular targeting of liposomal nanoparticles to tumor microenvironment","volume":"8","author":"Zhao","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"B72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.3390\/ijms23042034","article-title":"PLGA-based composites for various biomedical applications","volume":"23","author":"Rocha","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"115128","DOI":"10.1016\/j.carbpol.2019.115128","article-title":"Polyethylenimine-coated PLGA nanoparticles-encapsulated Angelica sinensis polysaccharide as an adjuvant to enhance immune responses","volume":"223","author":"Gu","year":"2019","journal-title":"Carbohydr Polym"},{"key":"B75","doi-asserted-by":"publisher","first-page":"128742","DOI":"10.1016\/j.foodchem.2020.128742","article-title":"Combination of carotenoids from Spirulina and PLA\/PLGA or PHB: New options to obtain bioactive nanoparticles","volume":"346","author":"Santos Assuncao","year":"2021","journal-title":"Food Chem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2019.06.205","article-title":"Polylactide cellulose-based nanocomposites","volume":"137","author":"Vatansever","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B78","doi-asserted-by":"publisher","first-page":"127219","DOI":"10.1016\/j.ijbiomac.2023.127219","article-title":"Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma","volume":"253","author":"Huang","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202307273","article-title":"Co-delivery of siNRF2 and sorafenib by a \u201cClick\u201d Dual functioned hyperbranched nanocarrier for synergistically inducing ferroptosis in hepatocellular carcinoma","volume":"20","author":"Tong","year":"2024","journal-title":"Small"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2023.11.109","article-title":"Dual-drug controllable co-assembly nanosystem for targeted and synergistic treatment of hepatocellular carcinoma","volume":"656","author":"Le","year":"2024","journal-title":"J Colloid Interface Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.04.002","article-title":"Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy","volume":"345","author":"Tran","year":"2022","journal-title":"J Control Release"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S57934","article-title":"Immunotoxicity of silicon dioxide nanoparticles with different sizes and electrostatic charge","author":"Kim","year":"2014","journal-title":"Int J Nanomedicine"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26051398","article-title":"Signaling pathways regulated by silica nanoparticles","volume":"26","author":"Hsu","year":"2021","journal-title":"Molecules"},{"key":"B84","doi-asserted-by":"publisher","first-page":"102569","DOI":"10.1016\/j.redox.2022.102569","article-title":"Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress","volume":"59","author":"Abulikemu","year":"2023","journal-title":"Redox Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.08.021","article-title":"Core-shell cisplatin\/SiO(2) nanocapsules combined with PTC-209 overcome chemotherapy-Acquired and intrinsic resistance in hepatocellular carcinoma","volume":"170","author":"Li","year":"2023","journal-title":"Acta Biomater"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.12.235","article-title":"Synthesis and characterization of silica nanoparticles from rice ashes coated with chitosan\/cancer cell membrane for hepatocellular cancer treatment","volume":"228","author":"Espinoza","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.18632\/aging.206013","article-title":"Degejirifu and X. Yan. 2021. Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer","volume":"13","author":"Wen","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2011.09.013","article-title":"Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system","volume":"365","author":"Ji","year":"2012","journal-title":"J Colloid Interface Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001000","article-title":"Intratumorally CpG immunotherapy with carbon nanotubes inhibits local tumor growth and liver metastasis by suppressing the epithelial-mesenchymal transition of colon cancer cells","volume":"32","author":"Jin","year":"2021","journal-title":"Anticancer Drugs"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b02595","article-title":"Anomalously fast diffusion of targeted carbon nanotubes in cellular spheroids","volume":"9","author":"Wang","year":"2015","journal-title":"ACS Nano"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b01440","article-title":"Rattle-structured rough nanocapsules with in-situ-formed gold nanorod cores for complementary gene\/chemo\/photothermal therapy","volume":"12","author":"Chen","year":"2018","journal-title":"ACS Nano"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2017.07.011","article-title":"Sensitive detection of brucine an anti-metastatic drug for hepatocellular carcinoma at carbon nanotubes - nafion composite based biosensor","volume":"98","author":"Savalia","year":"2017","journal-title":"Biosens Bioelectron"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666161216144218","article-title":"Recent advances of graphene-based hybrids with magnetic nanoparticles for biomedical applications","volume":"24","author":"Alegret","year":"2017","journal-title":"Curr Med Chem"},{"key":"B94","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12989-016-0168-y","article-title":"Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms","volume":"13","author":"Ou","year":"2016","journal-title":"Part Fibre Toxicol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"12558","DOI":"10.3390\/ijms232012558","article-title":"Graphene quantum dots modified upconversion nanoparticles for photodynamic therapy","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b18410","article-title":"A dual-targeting functionalized graphene film for rapid and highly sensitive fluorescence imaging detection of hepatocellular carcinoma circulating tumor cells","volume":"11","author":"Wu","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s1608","article-title":"Magnetic nanoparticles for gene and drug delivery","volume":"3","author":"McBain","year":"2008","journal-title":"Int J Nanomedicine"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e1901058","DOI":"10.1002\/adhm.201901058","article-title":"Magnetic nanoparticles in cancer therapy and diagnosis","volume":"9","author":"Farzin","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.3390\/ijms24065282","article-title":"(198)Au-coated superparamagnetic iron oxide nanoparticles for dual magnetic hyperthermia and radionuclide therapy of hepatocellular carcinoma","volume":"24","author":"Gharibkandi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12951-024-02469-6","article-title":"Homologous-magnetic dual-targeted metal-organic framework to improve the Anti-hepatocellular carcinoma efficacy of PD-1 inhibitor","volume":"22","author":"Guo","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1237361","article-title":"Tumor microenvironment responsive metal nanoparticles in cancer immunotherapy","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26113085","article-title":"Functionalization of metal and carbon nanoparticles with potential in cancer theranostics","volume":"26","author":"Mauro","year":"2021","journal-title":"Molecules"},{"key":"B103","doi-asserted-by":"publisher","first-page":"112394","DOI":"10.1016\/j.msec.2021.112394","article-title":"Alpha-ketoglutarate decorated iron oxide-gold core-shell nanoparticles for active mitochondrial targeting and radiosensitization enhancement in hepatocellular carcinoma","volume":"129","author":"Sood","year":"2021","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b07486","article-title":"Janus gold nanoplatform for synergetic chemoradiotherapy and computed tomography imaging of hepatocellular carcinoma","volume":"11","author":"Wang","year":"2017","journal-title":"ACS Nano"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2021.10.003","article-title":"Fenton metal nanomedicines for imaging-guided combinatorial chemodynamic therapy against cancer","volume":"17","author":"Liu","year":"2022","journal-title":"Asian J Pharm Sci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201910815","article-title":"Mo(2) C-derived polyoxometalate for NIR-II photoacoustic imaging-guided chemodynamic\/photothermal synergistic therapy","volume":"58","author":"Liu","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.7150\/thno.80887","article-title":"Multifunctional nanomedicines-enabled chemodynamic-synergized multimodal tumor therapy via Fenton and Fenton-like reactions","volume":"13","author":"Gao","year":"2023","journal-title":"Theranostics"},{"key":"B108","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jconrel.2020.06.032","article-title":"Photothermal therapy","volume":"325","author":"Zhi","year":"2020","journal-title":"J Control Release"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1039\/D1CS00074H","article-title":"Emerging photothermal-derived multimodal synergistic therapy in combating bacterial infections","volume":"50","author":"Huo","year":"2021","journal-title":"Chem Soc Rev"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0410-2","article-title":"Clinical development and potential of photothermal and photodynamic therapies for cancer","volume":"17","author":"Li","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1039\/D0BM01158D","article-title":"Nanomedicine-based tumor photothermal therapy synergized immunotherapy","volume":"8","author":"Shang","year":"2020","journal-title":"Biomater Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20114","article-title":"Photodynamic therapy of cancer: an update","volume":"61","author":"Agostinis","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201701211","article-title":"Nanocarrier-mediated photochemotherapy and photoradiotherapy","volume":"7","author":"Denkova","year":"2018","journal-title":"Adv Healthc Mater"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.07.049","article-title":"Photodynamic therapy - mechanisms, photosensitizers and combinations","volume":"106","author":"Kwiatkowski","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B116","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative approaches to cancer immunotherapy","volume":"5","author":"Szeto","year":"2019","journal-title":"Trends Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1039\/C9CS00648F","article-title":"Multifunctional sonosensitizers in sonodynamic cancer therapy","volume":"49","author":"Son","year":"2020","journal-title":"Chem Soc Rev"},{"key":"B120","doi-asserted-by":"publisher","first-page":"106617","DOI":"10.1016\/j.ultsonch.2023.106617","article-title":"Sonodynamic therapy-based nanoplatforms for combating bacterial infections","volume":"100","author":"Xu","year":"2023","journal-title":"Ultrason Sonochem"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.10.037","article-title":"Sonodynamic therapy-derived multimodal synergistic cancer therapy","volume":"497","author":"Xu","year":"2021","journal-title":"Cancer Lett"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer, (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-024-02085-8","article-title":"Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","first-page":"892-908.e11","DOI":"10.1016\/j.cmet.2020.04.011","article-title":"Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis","volume":"31","author":"Jian","year":"2020","journal-title":"Cell Metab"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S223920","article-title":"Design and characterisation of novel sorafenib-loaded carbon nanotubes with distinct tumour-suppressive activity in hepatocellular carcinoma","volume":"14","author":"Elsayed","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2016-0402","article-title":"Biomacromolecule\/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy","volume":"12","author":"Zhang","year":"2017","journal-title":"Nanomedicine (Lond)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2022.01.003","article-title":"CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment","volume":"17","author":"Wang","year":"2022","journal-title":"Bioact Mater"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207118","article-title":"Remodeling serine synthesis and metabolism via nanoparticles (NPs)-mediated CFL1 silencing to enhance the sensitivity of hepatocellular carcinoma to sorafenib","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.01.021","article-title":"Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo","volume":"331","author":"Younis","year":"2021","journal-title":"J Control Release"},{"key":"B131","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13046-019-1216-x","article-title":"Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib","volume":"38","author":"Zheng","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.10.031","article-title":"A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma","volume":"468","author":"Hu","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2022.12.022","article-title":"Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy","volume":"157","author":"Cao","year":"2023","journal-title":"Acta Biomater"},{"key":"B134","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B135","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12943-020-01281-8","article-title":"N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating beta-catenin signaling","volume":"19","author":"Xu","year":"2020","journal-title":"Mol Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c01453","article-title":"A hepatocellular carcinoma targeting nanostrategy with hypoxia-ameliorating and photothermal abilities that, combined with immunotherapy, inhibits metastasis and recurrence","volume":"14","author":"Zhou","year":"2020","journal-title":"ACS Nano"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01116-x","article-title":"Lenvatinib: A review in hepatocellular carcinoma","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B138","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4140","article-title":"Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma","volume":"82","author":"Hu","year":"2022","journal-title":"Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"13071","DOI":"10.3390\/ijms222313071","article-title":"Evaluating the effect of lenvatinib on sorafenib-resistant hepatocellular carcinoma cells","volume":"22","author":"Shi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.01.041","article-title":"N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells properties and lenvatinib resistance through WNT\/\u03b2-catenin and hippo signaling pathways","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in management of solid tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncologist"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.1","article-title":"Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib","volume":"12","author":"Hiraoka","year":"2023","journal-title":"Cancer Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2023.01.144","article-title":"A multifunctional nanotheranostic agent based on Lenvatinib for multimodal synergistic hepatocellular carcinoma therapy with remarkably enhanced efficacy","volume":"638","author":"Xu","year":"2023","journal-title":"J Colloid Interface Sci"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/nano12122048","article-title":"Flower-like composite material delivery of co-packaged lenvatinib and bufalin prevents the migration and invasion of cholangiocarcinoma","volume":"12","author":"Ning","year":"2022","journal-title":"Nanomaterials (Basel)"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1851492","article-title":"PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1)","volume":"17","author":"Luo","year":"2021","journal-title":"Autophagy"},{"key":"B147","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41392-022-00959-3","article-title":"Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2017.1384862","article-title":"In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer","volume":"24","author":"Ni","year":"2017","journal-title":"Drug Delivery"},{"key":"B149","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.3390\/ijms23148025","article-title":"Targeted co-delivery of gefitinib and rapamycin by aptamer-modified nanoparticles overcomes EGFR-TKI resistance in NSCLC via promoting autophagy","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B150","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12951-015-0121-5","article-title":"Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance","volume":"13","author":"Zhao","year":"2015","journal-title":"J Nanobiotechnology"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S92436","article-title":"Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance","volume":"10","author":"Yu","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0505","article-title":"Oligosaccharyltransferase inhibition overcomes therapeutic resistance to EGFR tyrosine kinase inhibitors","volume":"78","author":"Lopez Sambrooks","year":"2018","journal-title":"Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2015.01.009","article-title":"Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells","volume":"11","author":"Liu","year":"2015","journal-title":"Nanomedicine"},{"key":"B154","doi-asserted-by":"publisher","first-page":"118769","DOI":"10.1016\/j.ijpharm.2019.118769","article-title":"Biocompatible co-loading vehicles for delivering both nanoplatin cores and siRNA to treat hepatocellular carcinoma","volume":"572","author":"Li","year":"2019","journal-title":"Int J Pharm"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.1c09610","article-title":"TPGS\u2013galactose-modified polydopamine co-delivery nanoparticles of nitric oxide donor and doxorubicin for targeted chemo\u2013photothermal therapy against drug-resistant hepatocellular carcinoma","volume":"13","author":"Du","year":"2021","journal-title":"ACS Appl Materials Interfaces"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2015.11.062","article-title":"Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent","volume":"60","author":"Ngernyuang","year":"2016","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.03.072","article-title":"Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes","volume":"35","author":"Yin","year":"2014","journal-title":"Biomaterials"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.11.040","article-title":"Combination therapy with doxorubicin-loaded galactosylated poly(ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer","volume":"116","author":"Singh","year":"2017","journal-title":"Biomaterials"},{"key":"B159","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-023-01797-9","article-title":"Nanomaterials in tumor immunotherapy: new strategies and challenges","volume":"22","author":"Zhu","year":"2023","journal-title":"Mol Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204932","article-title":"Hybrid nanomaterials for cancer immunotherapy","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B161","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12951-023-01920-4","article-title":"Biomedical application of 2D nanomaterials in neuroscience","volume":"21","author":"Li","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discovery"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S363237","article-title":"The effects of a novel curcumin derivative loaded long-circulating solid lipid nanoparticle on the MHCC-97H liver cancer cells and pharmacokinetic behavior","volume":"17","author":"Wei","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.195.2.7724772","article-title":"Clinical results with Resovist: a phase 2 clinical trial","volume":"195","author":"Reimer","year":"1995","journal-title":"Radiology"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.193.3.7972804","article-title":"Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging","volume":"193","author":"Bellin","year":"1994","journal-title":"Radiology"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30040-8","article-title":"Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial","volume":"4","author":"Merle","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12951-022-01467-w","article-title":"A clinical trial of super-stable homogeneous lipiodol-nanoICG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection","volume":"20","author":"He","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"B168","doi-asserted-by":"publisher","first-page":"104151","DOI":"10.1016\/j.ebiom.2022.104151","article-title":"Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","volume":"82","author":"Ceelen","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1496498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:14:04Z","timestamp":1740726844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1496498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":168,"alternative-id":["10.3389\/fimmu.2025.1496498"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1496498","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"1496498"}}